No To Five, Yes To Three: NICE Decides On Funding For Drugs In England
NICE To Review Vyndaqel Guidance Quickly If New Pricing Deal Is Reached
Pfizer has been unsuccessful in its appeal against the health technology assessment body’s rejection of the rare heart disease drug, Vyndaqel. Meanwhile, Dr Falk Pharma has received the all-clear to make Jorveza (budesonide) available on the National Health Service for eosinophilic esophagitis.
You may also be interested in...
Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.
Pemazyre Wins Cost-Effectiveness Thumbs Up For Rare Bile Duct Cancer In England
Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.
NICE OKs Sarclisa & Mayzent For Funding In England, But Rejects Vindaqel
The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.